Skip to main content

Kathleen Ann Cooney

George Barth Geller Distinguished Professor of Medicine
Medicine, Medical Oncology
DUMC 3703, Duke North Hospital Suite 1102, Durham, NC 27710
40 Duke Medicine Circle, Davison Bldg, Suite 401, 401A, Durham, NC 27710

Overview


Dr. Cooney is Chair of the Duke Department of Medicine. 

She is a medical oncologist focused in caring for men with prostate cancer, and is internationally known for her investigations focused on the genetic epidemiology of prostate cancer.

Her research led to the important discovery of a recurrent mutation in the HOXB13 gene that increases the chances of being diagnosed with prostate cancer and is estimated to account for 5 percent of hereditary prostate cancer cases worldwide. Since men with HOXB13 mutations are at an increased risk of prostate cancer, they may benefit from participation in screening and potentially prevention protocols in the future.

Dr. Cooney’s research continues with a focus on identifying germline mutations associated with lethal and aggressive prostate cancer as well as prostate cancer in African American men.

Current Appointments & Affiliations


George Barth Geller Distinguished Professor of Medicine · 2020 - Present Medicine, Medical Oncology, Medicine
Professor of Medicine · 2018 - Present Medicine, Medical Oncology, Medicine
Chair, Department of Medicine · 2018 - Present Medicine, Clinical Science Departments
Member of the Duke Cancer Institute · 2018 - Present Duke Cancer Institute, Institutes and Centers
Member of Duke Molecular Physiology Institute · 2022 - Present Duke Molecular Physiology Institute, Institutes and Centers

In the News


Published December 1, 2022
Family History, Gene Variants Put Black Men at Risk for Early Prostate Cancer
Published April 14, 2020
Duke Awards 29 University Distinguished Professorships
Published April 3, 2020
Men's Risk of Prostate Cancer Linked to Female Relatives' History of Breast, Ovarian Cancer

View All News

Recent Publications


Using gene and gene-set association tests to identify lethal prostate cancer genes.

Journal Article Prostate cancer and prostatic diseases · August 2024 BackgroundRecent advances in the detection and treatment of prostate cancer (PCa) have reduced morbidity and mortality from this common cancer. Despite these improvements, PCa remains the second leading cause of cancer death in men in the United S ... Full text Cite

Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry.

Journal Article Prostate · April 2023 BACKGROUND: Although men of African ancestry (AA) have the highest mortality rate from prostate cancer (PCa), relatively little is known about the germline variants that are associated with PCa risk in AA men. The goal of this study is to systematically ev ... Full text Link to item Cite

Clinician interest in clinical decision support for PSA-based prostate cancer screening.

Journal Article Urol Oncol · March 2023 OBJECTIVE: To evaluate the interest of primary care clinicians in utilizing CDS for PSA screening. Evidence suggests that electronic clinical decision support (CDS) may decrease low-value prostate-specific antigen (PSA) testing. However, physician attitude ... Full text Link to item Cite
View All Publications

Recent Grants


Genetic Variation in Cancer Risk and Outcomes in African Americans

ResearchPrincipal Investigator · Awarded by Wayne State University · 2024 - 2029

Characterizing the Genetic Landscape of Prostate Cancer in Young African American Men - HDRA

ResearchPrincipal Investigator · Awarded by Department of Defense · 2016 - 2022

The Contribution of Rare Variants in Familial Clustering of Prostate and Breast Cancer in African Americans

ResearchPrincipal Investigator · Awarded by Wayne State University · 2018 - 2020

View All Grants

Education, Training & Certifications


University of Pennsylvania, School of Medicine · 1984 M.D.